The quarter was weaker than the market expected on earnings. Published consensus was approximately a $0.60 per-share loss, versus Immunovant’s reported $0.75 loss, a meaningful miss rather than a routine in-line result. The gap reflects heavier development spending, not a revenue shortfall—the company remains pre-commercial.
| Metric | Q1 FY2027 | Q1 FY2026 / prior comparison | Market reference |
|---|---|---|---|
| R&D expense | $142.6 million | $101.2 million | — |
| G&A expense | $17.7 million | $26.0 million | — |
| Net loss | $153.2 million | $120.6 million | — |
| Net loss per share | $0.75 loss | $0.71 loss | ~$0.60 loss |
| Cash and equivalents | $797.8 million | — | — |
| Cash and equivalents, sequentially | $797.8 million | $902.1 million at March 31, 2026 | — |
Spending accelerated as the pipeline advanced. R&D rose 41% year over year to $142.6 million, primarily from IMVT-1402 clinical-trial and manufacturing activity, while G&A fell 32% to $17.7 million. The net result was a 27% larger loss, and the share count also increased to 206.3 million from 203.9 million sequentially, adding modest dilution. (Income Statement; Common stock)
The operational update was steady, not incremental. All six IMVT-1402 programs remain on track, with D2T RA and CLE updates expected in the second half of calendar 2026, GD and MG data in 2027, and CIDP and SjD data in 2028. That preserves the prior development framework but does not add a new catalyst or pull any milestone forward. (Corporate Updates)
Liquidity remains adequate, but the cushion narrowed. Cash fell $104.3 million, or about 12%, from March 31 to June 30, 2026, even as management continued to say it funds operations through a potential GD launch. The runway statement is reassuring but was already part of the standing setup; this filing provides no new financing or cash-flow improvement to offset the larger-than-expected quarterly loss. (Cash Position; Balance Sheet)
Net read: a modest negative financial print with unchanged clinical execution. The pipeline calendar held, but that was the expected baseline, while the $0.75 loss exceeded the roughly $0.60 consensus loss and cash consumption remained substantial. The filing therefore weakens near-term financial optics without materially changing the clinical timeline.
Read the original 8-K on SEC EDGAR ↗